

CURRICULUM VITAE
J. SHEPARD BRYAN, M.D.

WORK EXPERIENCE

Private Practice July 1995 - Present	Associated Retina Consultants Ltd. 1750 E Glendale Avenue Phoenix, AZ 85020
Clinical Instructor November 1995 - Present	Maricopa County Medical Center 2601 E. Roosevelt Phoenix, AZ 85006
Clinical Instructor 2006 – 2014	University of Arizona, College of Medicine Department of Ophthalmology
Clinical Assistant Professor 2014 – Present	University of Arizona, College of Medicine Department of Ophthalmology

PREVIOUS WORK EXPERIENCE

Sabbatical July 2007 - June 2008	Retina Institute of Hawaii 1620 Ala Moana Blvd. Honolulu, HI 96815
Private Practice November 1995- June 2007	Associated Retina Consultants Ltd. 1750 E Glendale Avenue Phoenix, AZ 85020
Private Practice July 1993-November 1995	Retina Associates, P.A. Clinical Instructor/University of Florida University Medical Center Consultant U.S. Naval Hospital Jacksonville, Florida

BOARD CERTIFICATION

May 1995	American Board of Ophthalmology Board Exam: 99% overall 99% retina section
January 2006	American Board of Ophthalmology, Recertified

EDUCATION

M.D. Degree May 1988	University of Florida College of Medicine Gainesville, Florida
B.S. Degree June 1984	Tufts University Medford, Massachusetts Summa Cum Laude in biology, Phi Beta Kappa, Teaching Assistant, Department of Biology

CURRICULUM VITAE
J. SHEPARD BRYAN, M.D.

POST GRADUATE TRAINING

Fellowship July 1992-June 1993	Vitreoretinal diseases and surgery University of British Columbia Department of Ophthalmology Vancouver, British Columbia Co-Directors: Alan L. Maberley, M.D. (604) 875-4299 William H. Ross, M.D. 604) 731-0404
Residency July 1989-June 1992	University of Florida College of Medicine Department of Ophthalmology Gainesville, Florida Chairman: Melvin L. Rubin, M.D. (904) 393-3451
Internship July 1988-June 1989	Orlando Regional Medical Center Department of Internal Medicine Orlando, Florida

PUBLICATIONS/PRESENTATIONS

Bryan, J.S., Hamed, L. Levator sparing nuclear oculomotor palsy: Clinical and magnetic resonance imaging findings. *Journal of Clinical Neuro-ophthalmology*. 12(1):26-30, 1992.

Bryan, J.S., Maberley, A.L. Suture fixated secondary PCIOLs in eyes following silicone oil removal. University of British Columbia Research Conference. Vancouver, B.C. May, 1993.

Bryan, J.S., Hamed, L. Swelling of the optic disc. Chapter in Margo, C., Mames, R., Hamed, L. (eds). *Diagnostic Problems in Clinical Ophthalmology*. W. B. Sanders Co., Orlando, Florida, 1993.

Bryan, J.S. Vitritis in the quiet eye. North Florida Ophthalmologic Society. Jacksonville, Florida. September, 1993.

Bryan, J.S. Prevention of eye injuries. City on the Move. Television program sponsored by Society to Prevent Blindness. Jacksonville, Florida. March, 1994

Bryan, J.S. Macular surgery in the 1990's. North Florida Ophthalmologic Society. Jacksonville, Florida. May, 1994.

Bryan, J.S. Results of panretinal photocoagulation. Florida Society of ophthalmology/ Diabetes 2000. Orlando, Florida, September, 1994.

Bryan, J.S., Friedman, S.M., Mames, R.N., Margo, C.E. Experimental vitreous replacement with perfluorotri-n-propylamine. *Archives of Ophthalmology*. 112: 1098-1102, 1994.

Bryan, J.S., Ross, W.H., Barloon, A.S. Management of retinal detachments secondary to cytomegalovirus retinitis. *Canadian Journal of Ophthalmology*. 29(3):129-133, 1994.

Bennett, Michael D. MD; Yee, Wendy MD; Bryan, J Shepard MD. Pegaptanib Combined With Intravitreal Injection of Moxifloxacin as Treatment of Wet Macular Degeneration. *Retina* 28(7):976-980, July/August 2008.
Sell, C.S., Bryan, J.S. Maculopathy from hand held diode laser pointer. *Archives of Ophthalmology* 117(11):1557-1558, 1999.

Bryan, J.S., Romania, A. Optic disc neovascularization associated with bacterial endocarditis. (Submitted). *Retina 2007 Symposium: Understanding New Developments and Treatment Methods for Vitreoretinal Diseases*. Presented by Associated Retina Consultants, Hilton Squaw Peak , Phoenix, Arizona March 3, 2007.

CURRICULUM VITAE J. SHEPARD BRYAN, M.D.

Turaka K, Bryan JS, Kwong HM Jr, Ziemianski MC.: Bilateral occlusive retinal vasculitis in a patient with primary antiphospholipid antibody syndrome, *Can J Ophthalmol.* 2012 Dec;47(6):e60-1. doi: 10.1016/j.jcjo.2012.07.010. Epub 2012 Sep 29.

Turaka K, Bryan JS, Gordon AJ, Reddy R, Kwong HM Jr, Sell CH.: Laser pointer induced macular damage: case report and mini review, *Int Ophthalmol.* 2012 Jun;32(3):293-7. doi: 10.1007/s10792-012-9555-z. Epub 2012 Apr 1.

Turaka K, Bryan JS, Gordon AJ, Kwong HM Jr, Reddy R, Tsipursky M, Sell CH.: Clinical and image-guided chorioretinal findings in long-chain 3-hydroxyacyl-coenzyme A dehydrogenase deficiency, *J Pediatr Endocrinol Metab.* 2012;25(5-6):565-7.

Turaka K, Bryan JS, De Souza S, Gordon AJ, Kwong HM Jr, Ziemianski MC, Reddy R, Sell CH.: Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution, *Clin Lymphoma Myeloma Leuk.* 2012 Dec;12(6):412-7. doi: 10.1016/j.clml.2012.07.006. Epub 2012 Sep 18.

Turaka K, Bryan JS.: Does fingolimod in multiple sclerosis patients cause macular edema?, *J Neurol.* 2012 Feb;259(2):386-8. doi: 10.1007/s00415-011-6367-4. Epub 2012 Jan 10.

Turaka K, Reddy R, Golshani A, Khaw WY, Bryan JS.: Bilateral ischemic maculopathy in acquired immune deficiency syndrome, *J Ophthalmic Inflamm Infect.* 2013 Jan 15;3(1):15. doi: 10.1186/1869-5760-3-15.

Turaka K, Gordon AJ, Patel S, Bryan JS, Kwong HM Jr, Dugel PU, Arogyasami RM.: Diagnostic and therapeutic challenges, *Retina.* 2013 Mar;33(3):661-5. doi: 10.1097/IAE.0b013e3182757374.

Tsipursky MS, Heller MA, De Souza SA, Gordon AJ, Bryan JS, Ziemianski MC, Sell CH.: Comparative evaluation of no dye assistance, indocyanine green and triamcinolone acetonide for internal limiting membrane peeling during macular hole surgery, *Retina.* 2013 Jun;33(6):1123-31. doi: 10.1097/IAE.0b013e31827b63ce.

RESEARCH

- 1995** Chiron Vision Vitrasert Study Center (Ganciclovir implant for treatment of CMV retinitis). Jacksonville, Florida
- Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP). Jacksonville, Florida
- Clinical Research Drug Study, Pimagedine Trial Carl T. Hayden VAMC. Phoenix, Arizona
- 1997** Clinical Research Drug Study, Genentech F0708g (rhIGF-1) Phoenix, Arizona
- 1998** Roche Clinical Drug Study, Valganciclovir (oral prodrug of ganciclovir for treatment of CMV retinitis) Phoenix, Arizona
- 1999** Pharmacia & Upjohn Company Phase III, Double Masked Study of SNET2, Pharmacia & Upjohn Company Phase III, Double Masked Study of SNET2, Neovascularization associated with Age-related Macular Degeneration. Phoenix, Arizona
- AMDRT Age-related Macular Degeneration Radiotherapy Trial. Phoenix, Arizona
- 2002** Alcon Research Ltd., An Evaluation of Efficacy and Safety of Posterior Juxtapapillary Injections of Anecortave Acetate 15 mg (0.5 ml of 30mg/ml Juxtapapillary Injections of Anecortave Acetate 15 mg (0.5 ml of 30mg/ml Exudative Age-Related Macular Degeneration (AMD) Eligible for Initial Treatment with Photodynamic therapy (PDT) Using Visudyne. Phoenix, Arizona

CURRICULUM VITAE
J. SHEPARD BRYAN, M.D.

- 2003** Genentech Inc. FVF2428g(FOCUS): A Phase I/II Single-Masked, Multicenter Study of the Safety, Tolerability, and Efficacy of Multiple-Dose Intravitreal Injections of rhuFab V2 in Combination with Verteporfin (Visudyne™) Photodynamic Therapy in Subjects with Neovascular Age-Related Macular Degeneration (AMD) Eligible for Initial Treatment with Photodynamic therapy (PDT) Using Visudyne. Phoenix, Arizona.
- Genentech, Inc. FVF2598g (MARINA): A Phase III, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of rhuFab V2 (Ranibizumab) in Subjects with Minimally Classic or Occult Subfoveal Neovascular Age-Related Macular Degeneration. Phoenix, Arizona
- 2004** Alcon C-02-60: An Evaluation of the Efficacy and Safety of Posterior Juxtapapillary Administrations of Anecortave Acetate for Depot Suspension (15 mg or 30 mg) Versus Sham Administration in Patients (Enrolled in Study "A" or Study "B") at Risk for Developing Sight-Threatening Choroidal Neovascularization (CNV) Due to Exudative Age-Related Macular Degeneration (AMD). Phoenix, AZ.
- Genentech, Inc.FVF3192g (PIER): A Phase IIIb, Multicenter, Randomized, Double-Masked, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization (CNV) with or without Classic CNV Secondary to Age-Related Macular Degeneration. Phoenix, Arizona
- 2005** Eyetech Pharmaceuticals Inc. Co-Developer: Pfizer, Inc. EOP1013:A Phase 2/3 Randomized, Controlled, Double-Masked, Multi-Center, Comparative Dose-Finding Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injections of 0.3, 0.03, or 0.003 mg Pegaptanib Sodium (Macugen®), Given as Often as Every 6 Weeks for 3 Years, to Sham Injections, in Subjects with Diabetic Macular Edema (DME) involving the Center of the Macula. Phoenix, Arizona
- Eyetech Pharmaceuticals Inc. Co-Developer: Pfizer, Inc EOP1012: A Phase 3B/4, Randomized, Active Controlled, Double-Masked, Single Dummy, Multi-Center Comparative Trial, in Parallel Groups, to Compare the Safety and Efficacy of Intravitreal Injections of Macugen® Given Every 6 Weeks for Up to 102 Weeks, Plus Sham Photodynamic Therapy (PDT), to Macugen® plus PDT with Visudyne® in Subjects with Predominantly Classic Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). Phoenix, Arizona
- Alcon C-04-59: Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients with Exudative Age-Related Macular Degeneration (AMD). Phoenix, Arizona
- Genentech, Inc. FVF3426g (HORIZON): An Open-Label, Multicenter Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Subfoveal Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) Who Have Completed the Treatment Phase of A Genentech-Sponsored Ranibizumab Study. Phoenix, Arizona
- Genentech, Inc. FVF3689g (SAILOR): A Phase IIIb, Single-Masked, Multicenter, Randomized Study to Evaluate the Safety and Tolerability of Ranibizumab in Naïve and Previously Treated Subjects with Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD). Phoenix, Arizona

CURRICULUM VITAE
J. SHEPARD BRYAN, M.D.

2006

Eyetech Pharmaceuticals Inc. Co-Developer: Pfizer, Inc EOP1014: An Exploratory Randomized, Double-Masked, Multi-Center, Multi-Dose, Comparative Trial, In Parallel Groups, To Explore the Safety and Efficacy of Three Different Doses of Intravitreal Injections of Pegaptanib Sodium (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks For 102 Weeks, In Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD). Phoenix, Arizona

Eyetech Pharmaceuticals Inc. Co-Developer: Pfizer, Inc EOP1023: A Phase IV, Open-Label, Multi-Center Trial of Maintenance Intravitreal Injections of Macugen[®] (Pegaptanib Sodium) Given Every 6 Weeks For 48 Weeks In Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With A Different Modality Resulting In Maculopathy Improvement. Phoenix, Arizona

Allergan, Inc. Protocol 206207-009: A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700 ug and 350 ug Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein Occlusion. Phoenix, Arizona

Regeneron Pharmaceuticals, Inc. Protocol VGFT-OD-0508 Clinical Evaluation of Anti-angiogenesis in the Retina Intravitreal Trial AMD Phase 2 (CLEAR-IT AMD-2): A Randomized, Controlled Study of the Safety, Tolerability and Biological Effect of Repeated Intravitreal Administration of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration. Phoenix, Arizona

2007

Eli Lilly and Company. Protocol B7A-MC-MBCU: The Effect of Ruboxistaurin on Clinically Significant Macular Edema in Patients with Diabetes Mellitus, as assessed by Optical Coherence Tomography. Principal Investigator. Phoenix, Arizona

Regeneron Pharmaceuticals, Inc , Protocol VGFT-OD-0605: A Randomized, Double Masked, Active Controlled Phase III Study of the Efficacy, Safety, and Tolerability of Repeated Doses of Intravitreal VEGF Trap in Subjects with Neovascular Age-Related Macular Degeneration. Phoenix, Arizona

Regeneron Pharmaceuticals, Inc , Protocol VGFT-OD-0702: An Open-Label, Long-Term, Safety, and Tolerability of Intravitreal VEGF Trap-Eye in Subjects with Neovascular Age-Related Macular Degeneration. Phoenix, Arizona

QLT Inc. Protocol BPD OCR 022: A Multicenter, Randomized, Single-masked Study Comparing Reduced-fluence Visudyne[®]-Lucentis[®] Combination Therapies and Lucentis Monotherapy in Subjects with CNV Secondary to AMD. Phoenix, Arizona

Genentech, Inc. FVF4165g (BRAVO): A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Branch Retinal Vein Occlusion. Phoenix, Arizona

Genentech, Inc. FVF4166g (CRUISE): A Phase III, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection Compared with Sham in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion. Phoenix, Arizona

Genentech, Inc. FVF4168g (RIDE): A Phase III, Double-Masked, Multicenter, Randomized, Sham-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus. Phoenix, Arizona

CURRICULUM VITAE

J. SHEPARD BRYAN, M.D.

- 2008** Thrombogenics, Inc. Protocol TG-MV-006: A Randomized, Placebo Controlled, Double-Masked, Multicenter Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. Phoenix, Arizona
- Opko Health, Inc. A Phase 3, Randomized, Double-masked, Parallel-assignment Study of Intravitreal Bevasiranib Sodium, Administered Every 8 or 12 Weeks as Maintenance Therapy Following Three Injections of Lucentis®
- Monotherapy Every 4 Weeks in Patients with Exudative Age-related Macular Degeneration (AMD). Phoenix, Arizona
- 2009** Regeneron Pharmaceuticals, Inc. Protocol VGFT-OD-0819: A Randomized, Double-Masked, Controlled Phase 3 Study of the Efficacy, Safety, and Tolerability of Repeated Intravitreal Administrations of VEGF Trap-Eye in Subjects with Macular Edema Secondary to Central Retinal Vein Occlusion (CRVO). Phoenix, Arizona
- Genentech FVF 4579g (HARBOR): A Phase III, Double-Masked, Multicenter, Randomized, Active Treatment-Controlled Study of the Efficacy and Safety of 0.5 mg and 2.0 mg Ranibizumab Administered Monthly or on an An-Needed Basis (PRN) in Patients with Subfoveal Neovascular Age-Related Macular Degeneration. Phoenix, Arizona
- 2010** GlaxoSmithKline MD7110852: A Phase 2b Dose-Ranging Study of Pazopanib Eye Drops versus Ranibizumab Intravitreal Injections for the Treatment of Neovascular Age-Related Macular Degeneration. Phoenix, Arizona
- 2011** Alcon Protocol C-10-083: Safety and Efficacy of ESBA1008 versus Lucentis® for the Treatment of Exudative Age-Related Macular Degeneration. Phoenix, Arizona
- Allergan, Inc. GMA-OZU-09-011: A Retrospective Data Collection Study in Patients Receiving Two or More Ozurdex™ (Dexamethasone Intravitreal Implant) 0.7 mg Injections for Retinal Vein Occlusion. Phoenix, Arizona
- Genentech FVF4967g (SHORE): A Multicenter Randomized Study for Evaluating Dosing Regimens for Treatment with Intravitreal Ranibizumab Injections in Subjects with Macular Edema Following Retinal Vein Occlusion. Phoenix, Arizona
- GlaxoSmithKline BAM114341: A Phase 2, Multi-centre, Randomized, Double-masked, Placebo-controlled, Parallel-group Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics and Pharmacodynamics of GSK933776 in Adult Patients with Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD). Phoenix, Arizona
- LPATH LT1009-Oph-003 (Nexus): A Phase 2A, Multi-Center, Masked, Randomized, Comparator-Controlled Study Evaluating iSONEP™ (Sonepcizumab [LT1009]) as Either Monotherapy or Adjunctive Therapy to Lucentis® or Avastin® Versus Lucentis® or Avastin® Alone in the Treatment of Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration. Phoenix, Arizona
- Regeneron VGFT-OD-0910: An Open-label, Long-term, Safety and Tolerability Extension Study of Intravitreal VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration. Phoenix, Arizona
- Regeneron VGFT-OD-1009: A Double-Masked, Randomized, Active-Controlled, Phase 3 Study of the Efficacy and Safety of Intravitreal Administration of VEGF Trap-Eye in Patients with Diabetic Macular Edema. Phoenix, Arizona

PROFESSIONAL ORGANIZATIONS

CURRICULUM VITAE
J. SHEPARD BRYAN, M.D.

- American Academy of Ophthalmology
- American Medical Association
- Arizona Ophthalmologic Society
- Maricopa County Medical Society
- Phoenix Ophthalmology Society
- American Society of Retina Specialist
- The Association for Research in Vision and Ophthalmology (ARVO)

LICENSURE

- Florida, California, Oregon, Georgia and Hawaii - past
- Arizona License # 23580